Medigen Biotechnology Corporation (3176) - Financial and Strategic SWOT ... DigitalJournal.com Its major product candidates include Telomelysin (OBP-301) oncolytic virus therapy for cancer; and PI-88 (muparfostat) first-in-class heparanase inhibitor. The company also offers HLA (human leukocyte antigen) kits and outsourced HLA typing services ... |
